Viles-Gonzalez Juan F, Reddy Vivek Y, Petru Jan, Mraz Tomas, Grossova Zuzana, Kralovec Stepan, Neuzil Petr
Cardiac Arrhythmia Service, Mount Sinai Heart, Mount Sinai School of Medicine, New York, NY, USA.
J Interv Card Electrophysiol. 2012 Jan;33(1):69-75. doi: 10.1007/s10840-011-9613-x. Epub 2011 Sep 21.
Percutaneous approaches to left atrial appendage (LAA) closure are being developed for stroke prophylaxis in atrial fibrillation patients as an alternative to warfarin. Non-randomized clinical trials suggested that the first of these devices, the percutaneous left atrial appendage transcatheter occlusion (PLAATO) device, is safe and reduces stroke risk. Percutaneous closure has the potential limitation of incomplete exclusion of LAA from the systemic circulation, which could potentially lead to thrombus formation and stroke. This study investigated the interaction between residual blood flow in the LAA after percutaneous closure with PLAATO and risk of stroke.
Data from the PLAATO trial current as of July 2010 was used for this analysis (n = 22). Mechanical occlusion using the PLAATO device was used in 22 patients (age 68 ± 5, CHADS(2) score = 3.03 ± 0.6). Warfarin and clopidogrel were stopped during follow-up in all but one patient due to development of pulmonary emboli. After an average follow-up of 58 ± 9 months, four out of 22 patients (16.7%) developed a new ischemic stroke/TIA, translating to an annualized embolic rate of 3.63%. There were no differences in the demographics (age, sex, and CHADS(2) score) among patients with and without stroke. Cardiac CT documented peri-device leak in three out of four patients with stroke and in seven out of nine (75% vs. 77%, p = 0.706) patients without stroke that agreed to have a follow-up cardiac CT (Chi squared with Yates correction for this interaction = 0.012, p = 0.912). TEE corroborated these results but failed to identify peri-device leak in three patients without stroke.
The main finding of our analysis suggests that in long-term follow-up, residual flow after LAA occlusion with the PLAATO device, as documented by cardiac CT, is ubiquitous but is not associated with an increased risk of stroke.
经皮左心耳(LAA)封堵术正作为华法林的替代方法用于房颤患者预防卒中。非随机临床试验表明,此类装置中的首个,即经皮左心耳经导管封堵(PLAATO)装置是安全的,且能降低卒中风险。经皮封堵术存在潜在局限性,即不能完全将左心耳排除在体循环之外,这可能会导致血栓形成和卒中。本研究调查了使用PLAATO进行经皮封堵术后左心耳内残余血流与卒中风险之间的相互关系。
本分析使用截至2010年7月的PLAATO试验数据(n = 22)。22例患者(年龄68±5岁,CHADS(2)评分= 3.03±0.6)使用PLAATO装置进行机械封堵。除1例患者因发生肺栓塞外,所有患者在随访期间均停用了华法林和氯吡格雷。平均随访58±9个月后,22例患者中有4例(16.7%)发生了新发缺血性卒中/短暂性脑缺血发作(TIA),年化栓塞率为3.63%。发生卒中和未发生卒中的患者在人口统计学特征(年龄、性别和CHADS(2)评分)方面无差异。心脏CT显示,4例发生卒中的患者中有3例以及9例同意接受随访心脏CT检查的未发生卒中的患者中有7例(75%对77%,p = 0.706)存在装置周围渗漏(对此相互作用进行Yates校正的卡方检验= 0.012,p = 0.912)。经食管超声心动图(TEE)证实了这些结果,但有3例未发生卒中的患者未发现装置周围渗漏。
我们分析的主要发现表明,在长期随访中,心脏CT记录显示,使用PLAATO装置封堵左心耳后残余血流普遍存在,但与卒中风险增加无关。